Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.

医学 安慰剂 中期分析 临时的 鼻咽癌 佐剂 放化疗 诱导化疗 化疗 辅助化疗 内科学 肿瘤科 临床试验 放射治疗 癌症 病理 乳腺癌 替代医学 考古 历史
作者
Hai‐Qiang Mai,Sai‐Lan Liu,Qiu-Yan Chen,Lin‐Quan Tang,Feng Jin,Ling Guo,Haiqing Luo,Ying Hu,Huai Liu,Jinhui Liang,Chong Zhao,Dong–Hua Luo,Hao‐Yuan Mo,Shanshan Guo,Li‐Ting Liu,Jibin Li,Lin Wang,Xue-Song Sun,Xiaoyun Nicole Li,Pan Wang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): 6001-6001 被引量:24
标识
DOI:10.1200/jco.2024.42.16_suppl.6001
摘要

6001 Background: Patients with locoregionally advanced nasopharyngeal carcinoma (LANPC) have a risk of disease relapse after induction chemotherapy (IC)-concurrent chemoradiotherapy (CCRT). Early phase trials indicated that tislelizumab (PD-1 inhibitor) plus IC followed by CCRT have the potential to deepen responses and extend survival in LANPC. Here, we report the interim results of a phase 3 trial to evaluate the efficacy and safety of tislelizumab plus IC, followed by CCRT and adjuvant tislelizumab therapy in LANPC. Methods: Patients with high-risk LANPC (stage III-IVa, AJCC 8 th Staging System, excluding T3N0, and T3N1 with retropharyngeal lymph nodes +) were randomized (1:1) to receive 200 mg tislelizumab or placebo + gemcitabine and cisplatin (GP) every 3 weeks (Q3W) for 3 cycles, followed by CCRT and adjuvant tislelizumab or placebo Q3W for up to an additional 8 cycles. Stratification factors were center and disease stage (III or IVa). Dual primary endpoints were complete response rate (CRR) after induction therapy and progression-free survival (PFS) per RECIST 1.1 by investigator under blinded review. The planned interim analysis (IA) for evaluating the first primary endpoint, CRR, was scheduled at 4 weeks after the completion of induction therapy to test whether addition of tislelizumab to standard IC significantly improved CRR, with allocated alpha at 0.005. Results: Between June 2022, and May 2023, 450 patients were randomized to tislelizumab arm (n = 223) and placebo arm (n = 227). Baseline characteristics were balanced between the two arms. At IA, 93.7% and 93.8% of patients completed 3 cycles of induction therapy in tislelizumab arm and placebo arm, respectively. Significant improvement in CRR was observed in tislelizumab arm vs placebo arm in the intent-to-treat population (ITT) (30.5% vs 16.7%; P = 0.0006). Improvement in CRR in tislelizumab arm vs placebo arm was consistent across key subgroups including disease stage (III [33.8% vs 20.7%]; IVa [28.7% vs 14.5%]), sex (male [28.3 % vs 15.7%]; female [38.0% vs 19.7%]), and ECOG PS (PS of 0 [28.8% vs 16.2%]; PS of 1 [40.6% vs 19.4%]). The ORR was 93.3% in the tislelizumab arm and 90.7% in the placebo arm. In safety population (tislelizumab arm, n=219; placebo arm, n=224), the incidence of Grade ≥3 TEAEs (40.6% vs 39.3%) and SAEs (2.3% vs 1.3%) were similar between two arms. Conclusions: The trial met its first primary endpoint with a statistically significant improvement of CRR with the addition of tislelizumab to standard IC in high-risk LANPC. Induction therapy with tislelizumab plus GP was generally well tolerated with manageable safety profile. Continued follow-up is being conducted to assess long-term efficacy and safety. Clinical trial information: NCT05211232 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
隐形曼青的应助被糊涂的向秋采纳,获得10
1秒前
搜集达人的应助被精明的甜瓜采纳,获得10
2秒前
1111111发布了新的文献求助10
2秒前
完美世界的应助被雯雯采纳,获得10
3秒前
3秒前
回望发布了新的文献求助10
3秒前
3秒前
4秒前
StarsFX发布了新的文献求助10
4秒前
刘佳琪发布了新的文献求助10
4秒前
4秒前
5秒前
5秒前
5秒前
可册册完成签到,获得积分10
5秒前
Catherine发布了新的文献求助10
6秒前
6秒前
笙笙发布了新的文献求助10
7秒前
笙笙发布了新的文献求助10
7秒前
7秒前
华仔的应助被三分之二采纳,获得10
7秒前
7秒前
syvshc的应助被parantal采纳,获得10
8秒前
Orange的应助被晟觞采纳,获得10
8秒前
8秒前
8秒前
9秒前
可爱的函函的应助被XIXIHAHA采纳,获得10
9秒前
Grace完成签到,获得积分10
9秒前
9秒前
9秒前
笙笙发布了新的文献求助10
9秒前
ethyl完成签到 ,获得积分10
10秒前
10秒前
情怀的应助被西陆采纳,获得10
10秒前
明理的千筹完成签到,获得积分10
10秒前
10秒前
笙笙发布了新的文献求助10
10秒前
笙笙发布了新的文献求助30
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177767
求助须知:如何正确求助?哪些是违规求助? 9568590
关于积分的说明 21799821
捐赠科研通 7772374
什么是DOI,文献DOI怎么找? 3432476
关于科研通互助平台的介绍 2556695
邀请新用户注册赠送积分活动 2478034